Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)

August 4, 2014 2:24 PM

Roth Capital affirms Ligand Pharma (Nasdaq: LGND) with a Buy rating and $92 price target following Q2 results and update ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found